By analyzing the CSF biomarkers, including the levels of Aβ, tau, and ubiquitin, we were able to stratify AD cases into five subgroups (Iqbal et al., 2005), each of which presents a different clinical profile, suggesting that the disease mechanisms among these groups might not be the same. The gene discussed is MAPT; the disease is Alzheimer disease.